Products Categories
CAS No.: | 130-26-7 |
---|---|
Name: | Clioquinol |
Article Data: | 18 |
Molecular Structure: | |
Formula: | C9H5ClINO |
Molecular Weight: | 305.502 |
Synonyms: | Barquinol;Chinoform;Chloroiodoquine;Cifoform;Dioquinol;Eczecidin;Enteroquinol;Enterozol;Iodochlorhydroxyquin;Iodochloroquine;Iodochloroxyquinoline;Iodoxyquinoline;NSC 3531;Nioform;Quinambicide;Quiniodochlor;Quinoform;Rheaform;Rheaform Boluses;Vioform;5-Chloro-7-iodo-8-oxyquinoline;5-Chloro-7-iodo-8-quinolinol;7-Iodo-5-chloro-8-hydroxyquinoline;8-Hydroxy-7-iodo-5-chloroquinoline;Amebil;Bactol;Clioquinol; |
EINECS: | 204-984-4 |
Density: | 2.047 g/cm3 |
Melting Point: | 175-183 °C |
Boiling Point: | 350.424 °C at 760 mmHg |
Flash Point: | 165.731 °C |
Solubility: | water: <0.1 g/100 mL at 20 °C |
Appearance: | Cream-colored to brownish-yellow powder |
Hazard Symbols: | T |
Risk Codes: | 25 |
Safety: | 36/37/39-45 |
Transport Information: | UN 2811 6.1/PG 3 |
PSA: | 33.12000 |
LogP: | 3.19840 |
Conditions | Yield |
---|---|
With 1-butyl-3-methyl-pyridinium dichloroiodate at 80℃; for 1h; Inert atmosphere; | 94% |
Stage #1: With iodine; tert-butylamine In chloroform; toluene at -78℃; Stage #2: 5-Chloro-8-hydroxyquinoline In chloroform; toluene at -78 - 20℃; for 0.75h; |
Conditions | Yield |
---|---|
With trichloroisocyanuric acid In acetonitrile at 20℃; for 2h; | 65% |
Conditions | Yield |
---|---|
With tetrachloromethane; iodine trichloride Behandeln des Reaktionsprodukts mit Wasser; | |
With iodine trichloride; acetic acid Behandeln des jeweils erhalten Reaktionsprodukts mit Wasser; | |
With hydrogenchloride; iodine trichloride Behandeln des jeweils erhalten Reaktionsprodukts mit Wasser; |
1-(5-chloro-7-iodoquinolin-8-yl)-4-<2-(2-methyl-5-nitro-1H-imidazolyl)ethyl>butandioate
A
5-chloro-7-iodoquinolin-8-ol
B
succinic acid
C
metronidazole
D
4-[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethoxy]-4-oxobutanoic acid
Conditions | Yield |
---|---|
With phosphate buffer; potassium chloride In methanol at 37℃; Rate constant; var. pH; also with human plasma and rat liver homogenate; |
1-(5-chloro-7-iodoquinolin-8-yl)-4-<2-(2-methyl-5-nitro-1H-imidazolyl)ethyl>phthalate
A
5-chloro-7-iodoquinolin-8-ol
B
benzene-1,2-dicarboxylic acid
C
metronidazole
D
1,2-benzenedicarboxylic acid, mono[2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl]ester
Conditions | Yield |
---|---|
With phosphate buffer; potassium chloride In methanol at 37℃; Rate constant; var. pH; also with human plasma and rat liver homogenate; |
5-chloro-7-iodoquinolin-8-ol
Conditions | Yield |
---|---|
With water |
5-chloro-7-iodoquinolin-8-ol
Conditions | Yield |
---|---|
With water; iodine; potassium iodide | |
With sodium hypochlorite; water; potassium iodide |
Conditions | Yield |
---|---|
anschl. Behandeln mit Wasser; |
5-chloro-7-iodoquinolin-8-yl ethanoate
5-chloro-7-iodoquinolin-8-ol
Conditions | Yield |
---|---|
With sodium hydroxide Heating; |
5-chloro-7-iodo-8-quinolinyl-β-D-glucopyranoside
A
β-D-glucose
B
5-chloro-7-iodoquinolin-8-ol
Conditions | Yield |
---|---|
With β-glucosidase from almonds; water at 37℃; for 4h; pH=7; Reagent/catalyst; Enzymatic reaction; |
Clioquinol is an antifungal drug and antiprotozoal drug. With the CAS NO.130-26-7, Clioquinol is a quinoline compound that has antibacterial and antifungal properties. It is found in topical preparations to treat skin infections such as infected eczema, athlete's foot and other fungal infections. It is also found in combination preparations with hydrocortisone. It can be found in eye and ear preparations. Clioquinol is mainly used for intestinal amoebic dysentery and bacillary dysentery,and diarrhea caused by taking antibiotics, diarrhea and other nerve.
Physical properties about Clioquinol are: (1)ACD/LogP: 4.171; (2)ACD/LogD (pH 5.5: 3.10; (3)ACD/LogD (pH 7.4): 2.47; (4)ACD/BCF (pH 5.5): 73.89; (5)ACD/BCF (pH 7.4): 17.47; (6)ACD/KOC (pH 5.5): 375.51; (7)ACD/KOC (pH 7.4): 88.78; (8)#H bond acceptors: 2; (9)#H bond donors: 1; (10)#Freely Rotating Bonds: 1; (11)Index of Refraction: 1.768; (12)Molar Refractivity: 61.87 cm3; (13)Molar Volume: 149.226 cm3; (14)Polarizability: 24.527 10-24cm3; (15)Surface Tension: 70.0690002441406 dyne/cm; (16)Density: 2.047 g/cm3; (17)Flash Point: 165.731 °C; (18)Enthalpy of Vaporization: 61.852 kJ/mol; (19)Boiling Point: 350.424 °C at 760 mmHg
When you are using this chemical, please be cautious about it as the following:
1. Wear suitable protective clothing, gloves and eye/face protection
2. In case of accident or if you feel unwell, seek medical advice immediately (show label where possible)
You can still convert the following datas into molecular structure:
(1)InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H;
(2)InChIKey=QCDFBFJGMNKBDO-UHFFFAOYSA-N;
(3)Smilesc12c(c(cc(c1O)I)Cl)cccn2
The toxicity data is as follows:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
cat | LD50 | oral | 400mg/kg (400mg/kg) | LIVER: OTHER CHANGES | American Journal of Tropical Medicine. Vol. 24, Pg. 29, 1944. |
chicken | LDLo | oral | 5gm/kg (5000mg/kg) | Science Reports of the Research Institutes, Tohoku University, Series C: Medicine. Vol. 36(1-4), Pg. 10, 1989. | |
dog | LD | oral | > 1gm/kg (1000mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 1566, 1973 | |
guinea pig | LDLo | oral | 175mg/kg (175mg/kg) | LIVER: OTHER CHANGES | American Journal of Tropical Medicine. Vol. 24, Pg. 29, 1944. |
guinea pig | LDLo | subcutaneous | 200mg/kg (200mg/kg) | BEHAVIORAL: ATAXIA | Science Reports of the Research Institutes, Tohoku University, Series C: Medicine. Vol. 36(1-4), Pg. 10, 1989. |
human | TDLo | oral | 1400mg/kg/20D (1400mg/kg) | BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS | Japanese Journal of Medical Science and Biology. Vol. 24, Pg. 195, 1971. |
mouse | LD50 | intraperitoneal | 590mg/kg (590mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 14, Pg. 75, 1977. | |
mouse | LD50 | oral | 69mg/kg (69mg/kg) | Archives of Toxicology, Supplement. Vol. 2, Pg. 371, 1979. | |
mouse | LD50 | subcutaneous | 5gm/kg (5000mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 14, Pg. 75, 1977. | |
rabbit | LDLo | oral | 250mg/kg (250mg/kg) | LIVER: FATTY LIVER DEGERATION LIVER: OTHER CHANGES KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)" | JAMA, Journal of the American Medical Association. Vol. 100, Pg. 1658, 1933. |
rat | LD50 | intraperitoneal | 3400mg/kg (3400mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 14, Pg. 75, 1977. | |
rat | LD50 | oral | > 5gm/kg (5000mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 14, Pg. 75, 1977. | |
rat | LD50 | subcutaneous | > 5gm/kg (5000mg/kg) | Oyo Yakuri. Pharmacometrics. Vol. 14, Pg. 75, 1977. | |
women | TDLo | oral | 11gm/kg/36W (11000mg/kg) | SENSE ORGANS AND SPECIAL SENSES: VISUAL FIELD CHANGES: EYE SENSE ORGANS AND SPECIAL SENSES: OPTIC NERVE NEUROPATHY: EYE | Lancet. Vol. 1, Pg. 1015, 1972. |